Peginesatide for the treatment of anemia due to chronic kidney disease – an unfulfilled promise

Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events

(2016) Joseph Kotarek et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

(2016) Iain C. Macdougall et al.   KIDNEY INTERNATIONAL

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

(2016) A Michael Lincoff et al.   LANCET

Nonclinical evaluation of the potential for mast cell activation by an erythropoietin analog

(2015) James L. Weaver et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management

(2014) D. Rampton et al.   HAEMATOLOGICA

Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)

(2014) Iain C. Macdougall et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Anaphylaxis and Hypotension after Administration of Peginesatide

(2014) Charles L. Bennett et al.   NEW ENGLAND JOURNAL OF MEDICINE

Relative safety of peginesatide and epoetin alfa

(2014) Eric D. Weinhandl et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis

(2013) Iain C. Macdougall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peginesatide in Patients with Anemia Undergoing Hemodialysis

(2013) Steven Fishbane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose-finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients

(2011) I. C. Macdougall et al.   Clinical Journal of the American Society of Nephrology

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

(2010) Scott D. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia

(2009) Iain C. Macdougall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3

(2008) Jesse A. Berlin et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Methoxy Polyethylene Glycol-Epoetin Beta

(2008) Monique P Curran et al.   DRUGS